Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6HJX7)

• Drug Name: RP-66364 Drug Info
• Synonyms: RP-60532; RP-69929

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DM6HJX7

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin G/H synthase (COX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[4]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[5]
Dexibuprofen	DMFYBD0	Ankylosing spondylitis	FA92.0	Approved	[6]
Ketorolac	DMI4EL5	Postoperative inflammation	1A00-CA43.1	Approved	[7]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[8]
Oxaprozin	DM9UB0P	Osteoarthritis	FA00-FA05	Approved	[9]
Aceclofenac	DMZDF0B	Inflammation	1A00-CA43.1	Approved	[10]
Lornoxicam	DMYZFXN	Migraine	8A80	Approved	[11]
Morniflumate	DM9UTDE	Otitis media	AA80-AB0Z	Approved	[12]

Drug(s) Targeting Leukotriene B4 receptor 1 (LTB4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LTB4	DME26RS	Human immunodeficiency virus infection	1C62	Phase 2	[13]
Amelubant	DMUMCB9	Pulmonary disease	1B10-1F85	Phase 2	[14]
Biomed 101	DMQ9KZW	Kidney cancer	2C90.0	Phase 1	[15]
LY293111	DM03FHA	Pancreatic cancer	2C10	Discontinued in Phase 2	[16]
SB-201993	DMIF4VJ	Psoriasis vulgaris	EA90	Discontinued in Phase 2	[17]
CI-949	DMN4QSW	Asthma	CA23	Discontinued in Phase 2	[18]
CP-195543	DM1OSUR	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[19]
LTB 019	DM6G0PN	Asthma	CA23	Discontinued in Phase 2	[20]
LY-223982	DMWB7DO	Asthma	CA23	Discontinued in Phase 2	[21]
CP-105696	DM1C4IN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene B4 receptor 1 (LTB4R)	TTN53ZF	LT4R1_HUMAN	Modulator	[2]
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN; PGH2_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003795)
• [2] WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist.
• [3] Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
• [4] Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
• [5] Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
• [6] Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
• [7] Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
• [8] Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
• [9] The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
• [10] Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
• [11] The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
• [12] Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
• [13] LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47.
• [14] Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63.
• [15] Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003.
• [16] The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096.
• [17] (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41.
• [18] Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8.
• [19] The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases. Curr Opin Drug Discov Devel. 1999 Nov;2(6):550-6.
• [20] Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17.
• [21] Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14.
• [22] 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997).